Hainan Haiyao Co Ltd

Hainan Haiyao Co Ltd operates with a debt-to-equity ratio of 1.63, indicating a capital structure that is significantly leveraged. The company's liquidity position is assessed as medium, with a current ratio of 0.69, suggesting that it may struggle to meet short-term obligations without additional financing. Despite a cash and equivalents balance of 368.697 million CNY, the firm's long-term debt of 3.343 billion CNY results in a negative net cash position, raising concerns about its ability to service debt in the medium term.

Profitability metrics are weak, with a return on equity of -0.77% and a return on assets of -0.21%, both significantly below the industry median for pharmaceutical firms. The company reported a net loss of 15.842 million CNY and an operating loss of 19.909 million CNY, indicating operational inefficiencies or declining demand for its products. Gross profit of 136.493 million CNY on revenue of 363.023 million CNY suggests a gross margin of 37.6%, which is in line with the industry average but insufficient to cover operating expenses.

The company's revenue is concentrated in a single geographic market, with no disclosed international operations, making it highly sensitive to domestic regulatory and economic shifts. No segment-specific revenue breakdown is available, but the absence of diversification increases exposure to localized risks such as pricing pressures or policy changes in the Chinese healthcare sector.

Looking ahead, the company's revenue outlook is uncertain, with no clear guidance provided in the latest financials. The operating cash flow of 21.999 million CNY and capital expenditure of -58.921 million CNY suggest that the firm is investing in operations but not generating sufficient cash to sustain growth without external financing. The risk assessment highlights liquidity as a medium concern, with dilution risk rated as low, though the negative net cash position remains a red flag.

Recent filings and transcripts do not provide additional insight into the company's strategic direction or operational performance. The absence of analyst commentary or management guidance beyond the latest revenue actual of 2.472 billion CNY leaves the market with limited visibility into the firm's near-term prospects.

Hainan Haiyao Co Ltd (000566.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s operational focus, establishing a baseline for sector-specific analysis. The risk profile for the company has also been initialized, with dilution risk assessed as low and liquidity risk rated as medium. These assessments offer initial insights into the capital structure stability and trading fluidity associated with the stock, though the low severity of these changes suggests they are foundational updates rather than acute shifts. From a market coverage perspective, the company is currently followed by two analysts, while data on top holders and index memberships remains unreported. This limited coverage profile indicates that institutional scrutiny may be nascent, potentially leaving room for future analyst engagement as the company’s sector classification becomes more standardized. These updates collectively refine the investment thesis for Hainan Haiyao by anchoring it in the Healthcare sector while highlighting moderate liquidity considerations. Investors should monitor whether the low dilution risk persists as the company navigates its pharmaceutical operations under the watch of its current analyst coverage.

Net income improved by 71.8% year-over-year in 2019, signaling a potential stabilization in profitability trends.

Operating income surged 73.7% year-over-year in 2019, indicating significant improvement in core operational efficiency.

Free cash flow increased by 70.1% year-over-year in 2019, suggesting better cash generation capabilities.

Dilution risk is assessed as low, providing some protection for existing shareholders against equity erosion.

The company maintains a positive book value of 2.05 billion CNY, offering a baseline asset cushion.

The debt-to-equity ratio of 1.63 is in the bottom quartile, indicating excessive leverage compared to peers.

Credit risk is flagged as high, raising concerns about the company's ability to meet its financial obligations.

Cash conversion of -1.39 is in the bottom quartile, highlighting severe inefficiency in generating cash from operations.

Revenue ¥191.5M, +3,0% YoY; Operating income +88,1% YoY.

• ▍Revenue ¥191.5M, +3,0% YoY
• ▍Operating income +88,1% YoY
• ▍Net income +84,7% YoY
• ▍Net margin -98.0%

Revenue ¥189.4M, −10,4% YoY; Operating income +8,5% YoY.

• ▍Revenue ¥189.4M, −10,4% YoY
• ▍Operating income +8,5% YoY
• ▍Net income +11,5% YoY
• ▍Net margin -44.3%

Revenue ¥243.7M, +5,8% YoY; Operating income +51,0% YoY.

• ▍Revenue ¥243.7M, +5,8% YoY
• ▍Operating income +51,0% YoY
• ▍Net income +51,2% YoY
• ▍Net margin -36.9%

Revenue ¥186.0M; Operating income -¥1.24B.

• ▍Revenue ¥186.0M
• ▍Operating income -¥1.24B
• ▍Net margin -661.4%

Revenue ¥211.3M; Operating income -¥98.6M.

• ▍Revenue ¥211.3M
• ▍Operating income -¥98.6M
• ▍Net margin -44.9%

Revenue ¥230.4M; Operating income -¥186.6M.

• ▍Revenue ¥230.4M
• ▍Operating income -¥186.6M
• ▍Net margin -80.1%

Revenue ¥831.2M, −16,1% YoY; Operating income +73,7% YoY.

• ▍Revenue ¥831.2M, −16,1% YoY
• ▍Operating income +73,7% YoY
• ▍Net income +71,8% YoY
• ▍Free cash flow +70,1% YoY
• ▍Net margin -51.7%

Revenue ¥990.7M, −33,0% YoY; Operating income −1 200,9% YoY.

• ▍Revenue ¥990.7M, −33,0% YoY
• ▍Operating income −1 200,9% YoY
• ▍Net income −1 332,3% YoY
• ▍Free cash flow −417,8% YoY
• ▍Net margin -154.0%

Revenue ¥1.48B, −16,9% YoY; Operating income −98,2% YoY.

• ▍Revenue ¥1.48B, −16,9% YoY
• ▍Operating income −98,2% YoY
• ▍Net income −1 112,7% YoY
• ▍Free cash flow −18,9% YoY
• ▍Net margin -7.2%

Revenue ¥1.78B, −13,6% YoY; Operating income +96,1% YoY.

• ▍Revenue ¥1.78B, −13,6% YoY
• ▍Operating income +96,1% YoY
• ▍Net income +100,7% YoY
• ▍Free cash flow +86,2% YoY
• ▍Net margin 0.6%

Revenue ¥2.06B; Operating income -¥1.55B.

• ▍Revenue ¥2.06B
• ▍Operating income -¥1.55B
• ▍Net margin -75.5%